Enterprise capital markets proceed to indicate excessive curiosity in corporations with a deal with regenerative medication from Europe and the US.
Since 2017 the market has proven distinctive development, as funding volumes elevated threefold to ca. EUR 1,000m in 2021.
Particularly gene and cell therapies within the Biotech sector proceed to be predominant drivers in regenerative medication. Nevertheless, funding volumes of MedTech corporations even have proven outstanding development in recent times.
These observations clearly point out the longer term potential that’s attributed to the market of regenerative medication.